Triple Agonists (GLP-1/GIP/Glucagon) Drug-Drug Interaction Table

What Is the Triple Agonist (GLP-1/GIP/Glucagon) Drug Class?

Triple agonists are a class of synthetic peptides engineered to activate three distinct G-protein-coupled receptors at once: the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR). This three-receptor strategy separates them from dual GLP-1/GIP agonists such as tirzepatide. The glucagon arm adds hepatic fat oxidation and energy expenditure effects that neither GLP-1 nor GIP agonism alone achieves at clinically meaningful levels.

Receptor Pharmacology

GLP-1R activation slows gastric emptying, stimulates glucose-dependent insulin secretion, and reduces appetite through central arcuate nucleus signaling. GIPR co-activation amplifies insulin secretion and modifies adipose lipolysis. Glucagon receptor activation increases hepatic glucose output and, at doses balanced against GLP-1R-mediated insulin secretion, raises basal metabolic rate by 10 to 20% in preclinical models without net hyperglycemia.

Retatrutide balances these three activities through a single acylated peptide backbone. The phase 2 dose-ranging trial (N=338) tested doses from 1 mg to 12 mg once weekly subcutaneous. At the 12 mg dose, mean weight loss reached 24.2% at 48 weeks versus 2.1% with placebo (P<0.0001). No approved triple agonist existed in the United States as of July 2025.

Structural Distinctions From Other Incretin Classes

Retatrutide contains a C18 fatty diacid chain for albumin binding, yielding a half-life of approximately 6 days and enabling once-weekly dosing. This prolonged half-life means that drug interaction effects on gastric emptying persist for the full dosing interval rather than tapering after 24 hours, unlike shorter-acting GLP-1 receptor agonists such as exenatide twice daily. The FDA prescribing information for semaglutide notes gastric emptying delay as a class interaction risk; retatrutide carries that same risk plus the additional hepatic pharmacokinetic changes driven by glucagon receptor agonism.

Mechanism of Drug-Drug Interactions

Triple agonists generate drug-drug interactions through three distinct pathways. Each pathway operates independently, and a single co-prescribed drug may be subject to more than one.

Pathway 1: Delayed Gastric Emptying

Delayed gastric emptying reduces the absorption rate of orally administered drugs. Peak plasma concentration (Cmax) falls and time to Cmax (Tmax) lengthens for drugs whose absorption depends on rapid gastric transit. The clinical consequence is most significant for drugs with narrow therapeutic indices where a 20 to 40% reduction in Cmax translates to subtherapeutic exposure.

Drugs most affected include:

• Levothyroxine: Cmax reduction of approximately 30% observed with semaglutide co-administration in a dedicated DDI study; a similar effect is expected with retatrutide. Take levothyroxine at least 60 minutes before the morning meal and at least 4 hours before any other oral medication per ATA guidance.
• Oral contraceptives (ethinyl estradiol/levonorgestrel): Tmax delayed by approximately 1.5 hours in the semaglutide phase 1 DDI program; Cmax for levonorgestrel fell 13%. FDA labeling for semaglutide recommends using a non-oral backup contraceptive method or switching to a non-oral formulation.
• Cyclosporine: Narrow therapeutic index; delayed absorption creates unpredictable trough-to-peak ratios. Monitor cyclosporine levels more frequently during triple agonist initiation and dose escalation.
• Digoxin: Absorption slowing may reduce Cmax by 15 to 25%; toxicity risk is lower than with agents that increase digoxin levels, but bradycardia monitoring remains appropriate.

Pathway 2: Glucagon-Receptor-Mediated Hepatic Effects

Glucagon receptor activation increases hepatic glucose production and upregulates cytochrome P450 activity, particularly CYP3A4 and CYP2C9. This is a pharmacokinetic interaction pathway that does not exist with pure GLP-1 agonists or dual GLP-1/GIP agonists. Preclinical data from Eli Lilly's retatrutide characterization work indicate that hepatic triglyceride content fell 81.1% from baseline at 48 weeks in patients receiving 12 mg. Reduced hepatic steatosis changes the hepatic extraction ratio of high-clearance drugs.

Warfarin is the highest-priority concern. CYP2C9 drives S-warfarin metabolism, and any change in hepatic CYP2C9 activity directly alters anticoagulant effect. Clinicians should check INR within 7 to 14 days of each dose escalation and after reaching the maintenance dose, then return to standard monitoring intervals once INR is stable. The American Heart Association's 2023 AF anticoagulation guidance lists metabolic syndrome and obesity-related NAFLD as independent factors that alter warfarin sensitivity, which supports heightened vigilance in exactly the patient population receiving triple agonists.

Pathway 3: Pharmacodynamic Insulin-Glucose Interactions

Triple agonists potentiate the glucose-lowering effect of all insulin secretagogues and exogenous insulin. The glucagon arm partially counteracts hypoglycemia by preserving counterregulatory response, but this protective effect is dose-dependent and does not fully offset co-administered insulin or sulfonylurea activity.

In the retatrutide phase 2 trial, hypoglycemia events in patients with type 2 diabetes who continued baseline insulin were more frequent at the 8 mg and 12 mg doses. Insulin dose reduction of 20 to 50% at triple agonist initiation is consistent with the approach used in tirzepatide trials: the SURPASS-5 trial (N=475) reduced insulin glargine by 20% at tirzepatide initiation, which reduced hypoglycemia without sacrificing glycemic control.

Complete Drug-Drug Interaction Table

The table below covers interactions expected based on class pharmacology, retatrutide phase 1/2 data, and extrapolation from the well-characterized semaglutide and tirzepatide DDI programs. Interaction severity uses a three-level scale: Major (avoid or requires mandatory monitoring), Moderate (adjust dose or timing; monitor), Minor (awareness only).

| Co-prescribed Drug | Interaction Pathway | Effect on Co-Drug | Severity | Clinical Action | |---|---|---|---|---| | Warfarin | Hepatic CYP2C9 induction (GCGR) | Reduced anticoagulant effect; variable INR | Major | Check INR at each dose escalation; target INR 2.0 to 3.0 | | Insulin (basal or bolus) | Pharmacodynamic: additive glucose lowering | Hypoglycemia risk | Major | Reduce insulin 20 to 50% at initiation; self-monitor BG daily | | Sulfonylureas (glipizide, glimepiride, glyburide) | Pharmacodynamic: additive insulin release | Hypoglycemia risk | Major | Reduce sulfonylurea 50% at initiation; consider discontinuation | | Cyclosporine / tacrolimus | Gastric emptying delay; CYP3A4 change | Unpredictable trough levels | Major | Measure drug levels q1 to 2 wk during dose escalation | | Levothyroxine | Gastric emptying delay | Reduced Cmax ~30% | Moderate | Administer ≥60 min before any other oral drug; recheck TSH at 6 wk | | Oral contraceptives (EE/LNG) | Gastric emptying delay | Cmax reduced ~13 to 20% | Moderate | Switch to non-oral contraception or add barrier method | | Digoxin | Gastric emptying delay | Cmax reduced ~15 to 25%; Tmax extended | Moderate | Monitor heart rate; check digoxin level if toxicity suspected | | Oral hypoglycemics: SGLT-2 inhibitors | Pharmacodynamic: additive glucose lowering | Volume depletion additive to GLP-1 natriuresis | Moderate | Ensure adequate hydration; monitor renal function q3 months | | Metformin | Minimal PK; GI side effects additive | Nausea/vomiting amplified | Minor | Titrate metformin dose slowly; extended-release formulation preferred | | Atorvastatin / rosuvastatin | Possible CYP3A4 change (GCGR-mediated) | Minor statin AUC change (<20%) | Minor | No dose change required; monitor for myalgia if statin dose is high | | Antihypertensives (ACEi, ARB, thiazide) | Additive blood pressure lowering; natriuresis | Orthostatic hypotension | Minor | Check standing BP at each visit during dose escalation | | Amlodipine | CYP3A4 substrate; possible minor exposure change | AUC change <15% expected | Minor | No action required unless symptomatic hypotension | | Amiodarone | CYP3A4/CYP2C9 inhibitor; warfarin co-prescribing common | Warfarin sensitivity compounded | Major | If on warfarin + amiodarone + triple agonist, weekly INR until stable | | Lithium | No direct PK interaction; volume depletion risk via natriuresis | Lithium toxicity if dehydrated | Moderate | Monitor serum lithium; ensure hydration; avoid diuretics | | Oral bisphosphonates (alendronate) | Gastric emptying delay may reduce already-low bioavailability | Efficacy loss possible | Minor | Take bisphosphonate on empty stomach ≥30 min before triple agonist |

Prescribing Framework for Triple Agonists

No FDA-approved labeling for retatrutide existed as of July 2025, but phase 2 and phase 3 trial protocols establish a de facto dosing framework that clinicians in early-access or clinical-trial settings follow.

Starting Dose and Titration Schedule

Retatrutide phase 2 used a structured titration:

• Weeks 1 to 4: 2 mg subcutaneous once weekly
• Weeks 5 to 8: 4 mg once weekly
• Weeks 9 to 12: 8 mg once weekly
• Week 13 onward: 12 mg once weekly (maximum dose)

Gastrointestinal adverse events drove dose reductions in 15.7% of participants receiving 12 mg in the phase 2 trial. Nausea was the most common adverse event (45.7% at 12 mg vs. 16.0% placebo). Vomiting occurred in 24.3% at 12 mg. Both resolved in most patients within 4 to 8 weeks of reaching a stable dose.

Injection Site and Formulation

Subcutaneous injection into the abdomen, thigh, or upper arm. Rotate injection sites weekly. No formulation data for oral retatrutide exist in published phase 2 data, though Eli Lilly has filed intellectual property around oral acylated peptide platforms. Until an oral formulation is approved, gastric-emptying-mediated DDIs remain confined to co-administered oral drugs rather than retatrutide itself.

Pre-Prescribing DDI Checklist

Before initiating any triple agonist, complete this five-step review:

1. Identify all narrow-therapeutic-index drugs in the medication list (warfarin, cyclosporine, tacrolimus, digoxin, lithium, levothyroxine).
2. Reduce insulin or sulfonylurea doses before the first injection.
3. Counsel on switching to non-oral contraception if the patient relies on combined oral contraceptives.
4. Establish a warfarin or calcineurin inhibitor monitoring schedule tied to dose-escalation dates.
5. Order baseline TSH if levothyroxine is on the medication list; recheck at 6 weeks after reaching maintenance dose.

Retatrutide in MASLD and MASH: Why the Glucagon Arm Matters

MASLD (metabolic dysfunction-associated steatotic liver disease, formerly NAFLD) affects an estimated 38% of adults globally according to a 2023 meta-analysis in the Journal of Hepatology. Standard GLP-1 receptor agonists reduce liver fat, but the effect is driven primarily by caloric restriction and weight loss rather than direct hepatic receptor activity. Adding glucagon receptor agonism changes the mechanism fundamentally.

Hepatic Fat Reduction Data

In the retatrutide phase 2 trial, MRI-PDFF-measured hepatic fat fraction fell from a mean of 15.2% at baseline to 3.0% at 48 weeks in the 12 mg group, a relative reduction of 81.1%. This compares favorably to semaglutide 2.4 mg, which reduced hepatic fat by approximately 40% in the NASH-CRN substudy of STEP-1. The GCGR component drives β-oxidation and mitochondrial biogenesis in hepatocytes through a cAMP-PKA-PGC1α pathway that is independent of weight loss.

MASH Fibrosis and DDI Implications

Liver fibrosis modifies drug metabolism. A patient progressing from MASLD F0, F1 to a post-treatment F0 state will have meaningfully different hepatic extraction ratios for high-clearance drugs. This is clinically favorable (improved drug metabolism) but creates a transient period of unpredictable pharmacokinetics during active fibrosis regression. Any drug with hepatic first-pass metabolism greater than 60% should be monitored during the first 6 months of triple agonist therapy in patients with baseline MASLD. The AASLD 2023 MASLD Practice Guidance does not yet address this DDI scenario specifically, because approved MASLD-targeted therapies using GCGR agonism were not available at the time of publication.

Adverse Effects Relevant to Drug Interactions

Gastrointestinal Effects and Oral Drug Absorption

Nausea and vomiting during dose escalation create secondary DDI risks. A patient who vomits within 2 hours of taking cyclosporine, tacrolimus, warfarin, or an oral contraceptive has effectively missed that dose. Establish a clear patient-education protocol: if vomiting occurs within 2 hours of an oral narrow-therapeutic-index drug, the patient should contact their provider before taking a replacement dose.

The American Society of Health-System Pharmacists recommends that patients taking cyclosporine or tacrolimus with any GI-motility-altering agent maintain a vomiting log and report to their transplant team within 24 hours of any emetic episode during dose escalation.

Cardiovascular Effects and Antihypertensive Combinations

Triple agonists lower blood pressure through three additive mechanisms: weight loss, natriuresis (GLP-1R-mediated), and a direct vascular effect of glucagon receptor agonism on vascular smooth muscle. In the retatrutide phase 2 trial, systolic BP fell 7.4 mmHg at 12 mg at 48 weeks. Patients on two or more antihypertensives may require dose reductions, particularly if baseline systolic BP is <130 mmHg at the time of triple agonist initiation.

The 2023 AHA/ACC Hypertension Guideline explicitly identifies GLP-1 receptor agonist therapy as a secondary cause of blood pressure reduction that may require antihypertensive de-escalation.

Pancreatitis Risk and Alcohol Interactions

GLP-1 receptor agonists carry a class-labeling warning for acute pancreatitis based on FDA safety reviews. Triple agonists are expected to carry the same warning once approved. Alcohol consumption raises independent pancreatitis risk. Co-prescribing any triple agonist with chronic alcohol use or with other drugs that cause pancreatitis (didanosine, valproate, azathioprine) requires explicit counseling and a low threshold for lipase monitoring.

Special Populations

Renal Impairment

Retatrutide is cleared by proteolytic degradation rather than renal excretion. No dose adjustment is expected for renal impairment based on the pharmacokinetic profile observed in the phase 2 trial. This mirrors the semaglutide profile, where the FDA label for Ozempic states no dose adjustment for renal impairment. However, patients with CKD stage 4 to 5 receiving triple agonists alongside metformin require more frequent renal function monitoring given GLP-1-class natriuretic effects.

Hepatic Impairment

Formal hepatic impairment pharmacokinetic studies for retatrutide were not published as of July 2025. For comparison, semaglutide showed no clinically meaningful change in AUC or Cmax across Child-Pugh A, B, or C in a dedicated hepatic impairment study. A similar finding is plausible for retatrutide given similar albumin-binding kinetics, but prescribers should await phase 3 subgroup data before assuming equivalent behavior in decompensated cirrhosis.

Pregnancy and Oral Contraceptive Failure

Triple agonists are presumed teratogenic based on rodent embryo-fetal toxicity data filed with phase 2 IND applications, consistent with the semaglutide label section 8.1. Because triple agonists reduce oral contraceptive Cmax, effective contraception requires a non-oral method. The ACOG 2024 Contraception in Women With Obesity guideline recommends intrauterine devices or subdermal implants as first-line options in patients receiving weight-loss pharmacotherapy who do not desire pregnancy. Patch or ring formulations may also circumvent gastric-emptying-related absorption issues.